News

Fierce Pharma10d
Takeda wades through more Vyvanse declines, muses DTC model as US pricing uncertainty looms
Takeda, coming off a high of 2024 growth, is pushing through what it says will be the worst of its Vyvanse-related declines.
Fierce Pharma8d
Fierce Pharma Asia—GSK's massive Hengrui deal; Takeda's revenue drop; Celltrion's major US plant buy
GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...